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Abstr"ct
Human islet amyloid polypetide (hIAPP) is a 37 amino acid peptide, co-secreted along with
insulin in the islets of Langerhans of pancreatic beta cells. Aggregation of hIAPP fibrils is
believed to be toxic to beta cells and responsible for beta cell dysfunction and death associated
with type 2 diabetes. Insulin has been found to act against the actions of hIAPP. The internal
sequence of insulin, HLVEALYLV, recognizes and binds the 10-19 region of hIAPP. Since
insulin reportedly blocks the formation of amyloid fibers, insulin analogs may protect cell
membranes from damage. In an effort to study this effect, truncated analogs of insulin, namely
HLVEALYLV and LVEALYLV, were synthesized and tested in the presence of hIAPP.
Carboxyfluorescein-encapsulating vesicles that mimic the $-cell were created using a 7:3 ratio
of the lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3(phospho-L-serine) (DOPS), respectively, and the percent leakage of fluorescent dye from the
vesicles in the presence of the peptides was calculated as compared to a 100% Triton-X
detergent-treated control. The activity of the truncated analogs was compared to that of insulin
under the same conditions. Whereas insulin was somewhat protective of the effects of hIAPP, the
shorter analogs were found to increase the damage caused by hIAPP rather than reducing it,
possibly by co-aggregating with the hIAPP.
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1. Introduct!on
1.1 D!"b#t#s M#ll!tus
D!"b#t#s !s " chron!c d!s#"s# !n wh!ch th# body c"nnot us# th# !nsul!n hormon# prop#rly,
du# to th# l"ck of !nsul!n or b#c"us# th# som"t!c c#lls "r# !ns#ns!t!v# to th# !nsul!n produc#d !n
th# body. Th# !nsul!n hormon# !s us#ful for th# tr"nsport"t!on of glucos# from th# blood !nto th#
som"t!c c#lls. Th# !nsul!n "ctu"lly "ct!v"t#s th# r#c#ptor for glucos# to come to the surface of th#
body c#lls. Th#n eventually glucos# !s conv#rt#d !nto th# ATP, wh!ch "cts "s th# #n#rgy for th#
body. Th# hormon# !nsul!n !s s#cr#t#d by th# b#t" c#lls of th# p"ncr#"s. Th# d#cr#"s#d
product!on of !nsul!n r#sults !n d!"b#t#s m#ll!tus. It !s m"!nly cl"ss!f!#d !n two forms: Typ# 1
d!"b#t#s "nd Typ# 2 d!"b#t#s.
Typ# 1 D!"b#t#s !s "lso known "s Insul!n D#p#nd#nt D!"b#t#s (IDDM) or Juv#n!l#-ons#t
D!"b#t#s. In th!s d!s#"s#, th# p"ncr#"s produc#s l!ttl# or no !nsul!n. Th!s usu"lly !s s##n !n
ch!ldr#n of "g#s 10-14 y#"rs. Th# f"ctors "ff#ct!ng th# d!s#"s# "r# #nv!ronm#nt"l, g#n#t!c, or
"uto-!mmun#. The d#v#lopm#nt of Typ# 1 d!"b#t#s m"y b# du# to !nf#ct!on or #nv!ronm#nt"l
"g#nts. Inf#ct!ous "g#nts "tt"ck th# b#t" c#lls; th#s# !nclud# v!rus#s l!k# mumps, rub#ll",
coxs"ck!# B4, "nd tox!c ch#m!c"ls "nd cytotox!ns r#l#"s#d !n th# body.1 In som# c"s#s, #xposur#
of ch!ldr#n to cow’s m!lk !n !nf"ncy m"y l#"d to Typ# 1 d!"b#t#s. Th# cow m!lk cont"!ns an
"lbum!n s#rum prot#!n c"ll#d Bov!n# S#rum Album!n (BSA), wh!ch "cts "s th# #nv!ronm#nt"l
tr!gg#r to produc# "nt!bod!#s "nd r#sults !n th# d#struct!on of th# !nsul!n produc!ng c#lls1. Som#
p#opl# "r# genetically susceptible to #nv!ronm#nt"l f"ctors, which cause changes in the genetic
code and decreased production of insulin, r#sulting !n th# d!s#"s#. Type 1 diabetes c"n b# s##n
both !n ch!ldr#n "nd "dults but usu"lly st"rts !n ch!ldhood. It !s usu"lly tr#"t#d by careful
monitoring of blood glucose and !nj#ct!ng !nsul!n "nd by ch"ng!ng d!#t"ry h"b!ts.
1

Typ! 2 D"#b!t!s "s #lso known #s Non-Insul"n D!p!nd!nt D"#b!t!s Mellitus (NIDDM)
or #dult-ons!t D"#b!t!s. Ninety percent of th! world popul#t"on d"#gnos!d w"th d"#b!t!s "s
suff!r"ng from Typ! 2 D"#b!t!s. Typ! 2 D"#b!t!s "s mostly obs!rv!d "n old!r p!opl! #nd p!opl!
who #r! suff!r"ng w"th hyp!rt!ns"on, ob!s"ty, #nd h"gh l!v!ls of blood chol!st!rol. Th"s "s th!
s"xth most pr!v#l!nt d"s!#s! th#t "s r!spons"bl! for h"gh morb"d"ty "n th! Un"t!d St#t!s of
Am!r"c#. It r!sults from # comb"n#t"on of d!cr!#s!d "nsul"n s!cr!t"on #nd th! d!v!lopm!nt of
"ns!ns"t"v"ty of th! body c!lls to th! "nsul"n "n th! body. Th! form#t"on of #mylo"d f"br"ls "n th!
b!t# c!lls of th! p#ncr!#s "s a ch#r#ct!r"st"c f!#tur! of Typ! 2 D"#b!t!s. Th!s! #mylo"d f"br"ls #r!
thought to be cytotox"c to th! b!t# c!lls of th! p#ncr!#s, which l!#ds to th! d!#th of th! b!t#
c!lls. Insul"n r!s"st#nc! #nd hyp!rt!ns"on #r! symptoms #ssoc"#t!d w"th syndrom! X, #lso
c#ll!d m!t#bol"c syndrom!.2
1.2.

Wh!t "s Amyl"n?
Amyl"n "s #lso known #s isl!t #mylo"d polyp!pt"d!. Isl!t #mylo"d polyp!pt"d! (IAPP) "s

pr!s!nt "n th! $-c!lls of th! isl!ts of L#ng!rh#ns of th! p#ncr!#s. Th"s hormon! "s co-synth!s"z!d
#nd co-s!cr!t!d #long w"th "nsul"n (approximately 1:100 ratio) "n th! $-c!lls of th! p#ncr!#s.3
Thus it acts as the synergistic partner to insulin in inhibiting the appearance of glucose in the
plasma.4 It "s # 37 #m"no #c"d long ch#"n th#t s!l!ct"v!ly "nh"b"ts "nsul"n st"mul#t!d glucos!
ut"l"z#t"on #nd glycog!n d!pos"t"on "n muscl!s, but "t do!s not #ff!ct #d"pocyt! glucos!
m!t#bol"sm. 5 Amyl"n f"b!rs or "sl!t #mylo"d polyp!pt"d! f"b!rs #r! pr!s!nt "n th! "sl!ts of
p#ncr!#t"c c!lls of p#t"!nts suff!r"ng from Typ! 2 D"#b!t!s.6 S"m"l#r protein f"b!rs #r! #ssoc"#t!d
w"th Alzh!"m!r’s d"s!#s! #nd Pr"on d"s!#s!s.1
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1.3.

Genes for Amyl!n
Synonyms for th! "myl#n g!n! "r! DAP "nd IAPP. Th! hum"n "myl#n g!n! #s loc"t!d on

chromosom! 12 of th! g!nom!7 (Entr!z G!n! ID: 3375). It cons#sts of thr!! !xons, two #ntrons,
" TATA-box, " CCAAT-s!qu!nc! "nd " GT-!l!m!nt.8 Its mRNA cons#sts of 1482 b"s! p"#rs.
Th! R!fs!q mRNA ID #s NM_00415.1. Th! Bl"st n r!sults for Hum"n "myl#n "g"#nst r!fs!q_rn"
got 111 bl"st h#ts "nd 98% #d!nt#t#!s for Ch#mp"nz!! (XM_001144800.1), 77% #d!nt#t#!s for
Dog (NM_001003233.1), "nd 80% #d!nt#t#!s for C"t (NM_001043338.1).
Th! "myl#n pr!cursor prot!#n cons#sts of 89 "m#no "c#d r!s#du!s (NP_000406.1). Its
structur! #s clos!ly r!l"t!d to th! c"lc#ton#n f"m#ly prot!#ns (PF00214). It h"s " d#sulf#d! bond
b!tw!!n pos#t#ons 35 "nd 40 "nd " prot!olyt#c cl!"v"g! s#t! "t th! 73rd pos#t#on. 9 Accord#ng to
th! Homolog!n!, th! prot!#n #s clos!ly r!l"t!d to "myl#n of Ch#mp"nz!! (G!n!ID: 741937). Th!
Clust"l w show!d th"t "myl#n p!pt#d! #s not !x"ctly th! s"m! #n "ll m"mm"l#"n sp!c#!s.10 Th!
"ct#v! p"rt of "myl#n #s d#ff!r!nt from sp!c#!s to sp!c#!s.11 Comp"r#son of th! s#m#l"r#t#!s
b!tw!!n IAPP "nd th! P f"m f"m#ly (Acc!ss#on numb!r: PF0024) p!pt#d! s!qu!nc!s shows th"t
th!s! p!pt#d!s m"y b#nd to structur"lly r!l"t!d r!c!ptors. 12

1.4.

Amyl!n/ hIAPP Funct!on
Amyl#n’s funct#on #s glyc!m#c control #n th! body. Insul#n low!rs th! blood glucos!

l!v!ls, "nd gluc"gon #ncr!"s!s th! blood glucos! l!v!l #n th! plasma.13 Amyl#n supports th!
insulin hormone from the inhibition of blood glucos! l!v!ls’ appearance by slow d!gr"d"t#on #n
th! body.14 Amyl#n m"#nly stops gluc"gon s!cr!t#ons dur#ng hyp!rglyc!m#" "nd th!r!for!
r!duc!s th! tot"l #nsul#n d!m"nd.15

3

1.5.

Amyl!n rol" !n D!#b"t"s M"ll!tus
Amyl!n h"s been !sol"t#d from p"ncr#"t!c "mylo!d fibr!ls !n p"t!#nts suff#r!ng w!th

D!"b#t#s M#ll!tus 2 "nd !nsul!nom"s.16 In the initial stage of the disease, the body becomes
insensitive to insulin, and in the later stages of the disease the degradation of the beta cells
increases and leads to the decreased production of insulin in the body. How#v#r, th# #x"ct
m#ch"n!sm !nvolv#d !n "myl!n c"us!ng D!"b#t#s M#ll!tus 2 !s unknown. A sp#c!f!c !mmun#
r#"ct!v!ty of "nt!bod!#s to IAPP h"s b##n found !n "mylo!d pl"qu#s "nd !n th# !sl#ts of
L"ng#rh"ns.17 Amyl!n forms "mylo!d f!b#rs !n b#t" !sl#t c#lls "nd !nduc#s th# d#"th of b#t"
c#lls.17 Th!s r#sults !n th# r#duc#d product!on of !nsul!n "nd c"us#s D!"b#t#s M#ll!tus.18

1.6.

Act!v" r"g!ons !n th" hIAPP
F!gur#1 ") shows th# full l#ngth of th# hum"n IAPP s#qu#nc# "nd 1b) shows th# full

l#ngth of th# r"t IAPP s#qu#nc# w!th th# thr## prol!n# "m!no "c!d r#s!du#s "t th# 25th, 28th, "nd
29th pos!t!ons. Hum"n IAPP (hIAPP) "nd r"t IAPP (rIAPP) "r# v#ry s!m!l"r #xc#pt for " f#w
"m!no "c!ds. Th# hIAPP forms "mylo!d f!br!ls, but rIAPP c"nnot form "mylo!d f!br!ls du# to
pr#s#nc# of th# thr## prol!n# r#s!du#s !n !ts s#qu#nc#. Th# r#s!du#s from 20 to 29 "r# th# "ct!v#
r#g!on for th# form"t!on of th# f!br!l b#c"us# th!s r#g!on !n!t!"lly w!ll form th# "nt!-p"r"ll#l b#t"
pl#"t#d sh##ts th"t r#sult !n "mylo!d f!br!l form"t!on. Th# 20 – 29 r#g!on of th!s polyp#pt!d# !s
th#r#for# cr!t!c"l for th# form"t!on of th# f!br!ls. Any ch"ng# !n th# s#qu#nc# or r#pl"c#m#nt of
"m!no "c!ds from 20 to 29 r#s!du#s m!ght h#lp !n th# r#duct!on of f!br!l form"t!on. Th# oth#r
pot#nt!"l r#g!ons th"t m!ght "ff#ct th# "mylo!g#n!c!ty, "p"rt from 20 to 29, "r# th# 30 to 37 "nd 8
to 20 r#g!ons. Th#s# r#g!ons "llow th# !ntr"mol#cul"r b#t" sh##t form"t!on !n hIAPP but not !n
rIAPP du# to th# pr#s#nc# of th# prol!n# "m!no "c!ds !n th# r"t form.

4

!) Human/hIAPP1-37 : +H3N-KCNTATCAT QRLANFLVHS SNNFGAILSS TNVGSNTYCONH2
b) R!t/rIAPP1-37:

+

H3N-KCNTATCAT QRLANFLVRS SNNLGPVLPP TNVGSNTY-

CONH2
Figure 1: Th! amino acid s!qu!nc! of hum"n "nd r"t IAPP "r! #llustr"t!d.

1.7.

Th! Thr!! D"m!ns"on#l Structur! of Amyl"n
Pr"v#ous stud#"s sugg"st th!t hIAPP "xh#b#ts ! r!ndom co#l structur" w#th sm!ll

compon"nts of $- h"l#c!l n!tur", wh#ch th"n tr!nsforms to % sh""t f#br#ls upon interaction with
the cell membrane. A r"c"nt study conf#rm"d th!t solubl" hIAPP h!s m!#nly !n unord"r"d
b!ckbon" structur". Ol#gom"rs of hIAPP r"pr"s"nt #nt"rm"d#!t"s #n th" p!th of f#br#l form!t#on.
Th"s" !lso cont!#n $- h"l#c!l structur"s. Th" thr""-d#m"ns#on!l structur" of th" hIAPP h!s b""n
stud#"d w#th h#gh r"solut#on t"chn#qu"s such !s "l"ctron m#croscopy, X-r!y d#ffr!ct#on !nd
"l"ctron d#ffr!ct#on. Th"s" stud#"s cl"!rly r"v"!l th!t hIAPP cont!#ns ! s#gn#f#c!nt !mount of w"ll
ord"r"d cross %-structur"s. Dur#ng f#br#l form!t#on, hIAPP #n#t#!lly und"rgo"s ! ch!ng" from !
r!ndom co#l to ! m#xtur" of % sh""t !nd $- h"l#c!l structur" conform!t#ons.18

1.8.

Import#nc! of Pr!s!nc! of Prol"n! R!s"du!s
Th" comp!r#son of th" hum!n IAPP s"qu"nc" !nd th" r!t IAPP s"qu"nc" within th" 20 -

29 r"g#on shows th" d#ff"r"nc" to be th" pr"s"nc" of thr"" prol#n" r"s#du"s #n th" r!t IAPP
s"qu"nc". Som" stud#"s sugg"st th!t th" pr"s"nc" of prol#n" r"s#du"s #n th" r!t IAPP s"qu"nc"
d"st!b#l#z"s th" form!t#on of th" b"t! sh""ts so th!t th" r!t c!nnot d"v"lop !mylo#d f#br#ls.

5

1.9.

Rol! of H"st"d"n! "n Amylo"d Form#t"on
Th! hIAPP cont"#ns " s#ngl! H#st#d#n! r!s#du! "t th! 18th pos#t#on, "nd #ts proton"t#on

st"t! d!p!nds on pH, "s #t ch"ng!s from th! #ntr"gr"nul"r to !xtr" gr"nul"r p"rt of th! b!t" c!lls.
Th! "ggr!g"t#on of "myl#n monom!rs #s cons#d!r"bly slow!r "t th! low!r pH of 4 th"n th! h#gh!r
pH of 8.8 of th! b!t" c!lls.18 Th! r"t! of "ggr!g"t#on of th! f#br#ls #ncr!"s!s dr"st#c"lly "t th!
low!r pH #n th! pr!s!nc! of s"lt. Th! single H#st#d#n! "m#no "c#d r!s#du! #s proton"t!d "t th!
low!r pH 4. Th#s proton"t!d st"t! c"n "ff!ct b!t" sh!!t fold#ng "s w!ll "s r!duc! z#nc b#nd#ng.
S#nc! Zn #s pos#t#v!ly ch"rg!d, proton"t#on would d!cr!"s! th! Zn b#nd#ng, whereas the
d!proton"t!d form "t th! h#gh!r pH 8.8 can interact with the metal ion. At th#s po#nt, th!
unstructur!d monom!rs t!nd to form th! b!t" sh!!t structure of th! f#br#l. Abov! th! pK" v"lu! of
th! h#st#d#n!, th! hAIPP r!"d#ly "ggr!g"t!s to form "mylo#d wh#l! th! "ggr!g"t#on #s slow!r "t
low!r pH.18

1.10. Eff!ct of pH #nd C#lc"um Conc!ntr#t"ons
pH #s th! #mport"nt f"ctor for m"#nt"#n#ng th! "ct#v! forms of th! hIAPP "nd insul#n #n
th! b!t" c!lls. If th!r! #s " ch"ng! #n th! pH of th! b!t" c!lls, th!n #t w#ll l!"d to f#br#l form"t#on
of th! hIAPP. Isl!t "mylo#d m"y "lso form du! to an #n"b#l#ty to clear th! IAPP from th! b!t"
c!lls. A ch"ng! #n th! pH #n th! b!t" c!lls "lso r!sults #n f#br#llog!n!s#s. In a medium of "c#d#c
pH, "myl#n #s #n th! "ct#v! form, "nd #f th!r! #s "n #ncr!"s! #n pH, such "s to 7.4 #n th!
!xtr"c!llul"r r!g#on, th!n th!r! is greater poss#b#l#ty for th! form"t#on of th! f#br#ls #n th! b!t"
c!lls. These hIAPP fibrils allow th! entry of an excess conc!ntr"t#on of extracellular c"lc#um
#ons, which leads to oxidative stress and apoptosis of th! b!t" c!lls.19
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1.11. St!ps Involv!d "n th! Form#t"on of th! Amylo"d F"br"ls
F!gur" 2 "xpl#!ns th" st"ps !n th" form#t!on of th" #mylo!d f!br!ls. Th!s f!gur" is #d#pt"d from
r"f"r"nc" 18.

Figure 2: Steps

involved in the formation of the Amyloid Fibrils are illustrated.

In!t!#lly, th" s!ngl" native monom"rs [A] of th" IAPP misfold #nd form th" m!sfold"d
monomers [B], #nd th"s" m!sfold"d monomers cl!ng to "#ch oth"r #nd form #ggr"g#t"s [C].
Th"s" #ggr"g#t"s #l!gn parallel to one another #nd form # b"t# sh""t form#t!on. This r"sults !n
th" form#t!on of th" protof!br!ls [D] #nd conv"rs!on of th" protof!br!ls !nto f!br!ls [E].
Subs"qu"ntly, mor" f!br!ls #ccumul#t" to form #mylo!d d"pos!ts [F].
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1.12. Poss!bl" Typ"s of L!p!d M"mbr#n" D!srupt!ons C#us"d by th" P"pt!d"s

Figure 3:

Typ!s of peptide and l"p"d m!mbr#n! interactions and possible membrane

d"srupt"on mechanisms.
Th!s f!gur" !s #d#pt"d from r"f"r"nc" [3]. An ov"rv!"w of th" g"n"r#l m"ch#n!sms of l!p!d
m"mbr#n" d!srupt!on is #s follows. [A] Th" unstructur"d p"pt!d"s #ppro#ch th" l!p!d m"mbr#n".
[B] Th" s!ngl" monom"r folds and attaches to th" l!p!d bi l#y"r m"mbr#n". [C] More monomers
join the p"pt!d" on th" m"mbr#n" surf#c". [D] Th" “B#rr"l-st#v" mod"l” !s form!ng # por" #cross
th" m"mbr#n". [E] Th" “Toro!dol wormhol"” !s wh"r" th" p"pt!d"s #nd l!p!ds #r" #l!gn!ng !n th"
por" of th" l!p!d m"mbr#n". [F] Th" “D"t"rg"nt-l!k"” or “c#rp"t mod"l” !s wh"r" th" h!gh

8

conc!ntr"t#on of th! p!pt#d!s "r! on th! surf"c! of th! l#p#d, r!sult#ng #n th! d#srupt#on of th! l#p#d
m!mbr"n!.
In g!n!r"l, p!pt#d!s p!rm!"b#l#z! l#p#d m!mbr"n!s by "ny of thr!! typ!s of poss#bl!
m!ch"n#sms. At h#gh!r conc!ntr"t#ons, p!pt#d!s m"y s!lf-"ss!mbl!, which r!sults #n th!
form"t#on of th! f#br#ls. Th! f#br#ls "ppro"ch th! l#p#d m!mbr"n!s "nd d#srupt #n "ny on! of th!
thr!! m!ch"n#sms. Th! f#rst on! #s th! “B"rr!l-st"v! mod!l” #n wh#ch th! p!pt#d!s form
tr"nsm!mbr"n! por!s2 [Fig 3D]. Th! s!cond on! #s th! “toro#d"l wormhol!” mod!l #n wh#ch th!
p!pt#d!s b#nd to th! p"r"ll!l surf"c!s of th! l#p#d m!mbr"n!s and cr!"t! pos#t#v! curv"tur!s "long
th! m!mbr"n!s. Th#s r!sults #n th! form"t#on of por!s. Th!n th! l#p#d "nd f#br#ls "l#gn #ns#d! th!
por!s of th! m!mbr"n!s "nd c"us! th! d!st"b#l#z"t#on #n th! m!mbr"n!s [F#g 3E]. Th! th#rd on!
#s c"ll!d th! “c"rp!t mod!l” or “d!t!rg!nt-l#k!” mod!l wh!r! th! p!pt#d!s r!s#d! on th! surf"c! of
th! m!mbr"n!s "nd us! th! d#ffus#on pr#nc#pl!, pulling apart the phospholipids, r!sult#ng #n th!
d#srupt#on [F#g 3F] .18

1.13. Th! Proc!ss of M!mbr"n! D#srupt#on by hIAPP
Th! "n#on#c l#p#ds #n th! phosphol#p#d m!mbr"n!s "r! mor! "ttr"ct#v! r!g#ons for th!
"tt"chm!nt of th! hAIPP "mylo#d f#br#ls. The positively charged N-terminus of hIAPP is
attracted to the negative membrane. Th! hydrophob#c n"tur! of th! hIAPP allows it to aggregate
with other molecules of itself, and th#s r!sults #n th! "ccumul"t#on. Subs!qu!ntly, th! nucl!"t#on
of th! p!pt#d! r!sults #n th! l!"k"g! of th! cont!nts of th! b!t" c!lls, due to alteration of both
m!mbr"n! structur! "nd funct#on, "nd f#n"lly l!"ds to th! c!ll’s d!"th.
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1.14. Ant!gon"st"c N!tur# of Insul"n "n th# F"b#r Form!t"on
Insul!n h"s an A ch"!n "nd B ch"!n !n !ts structur#. Th# B ch"!n !s th# !mport"nt r#g!on !n
th# !nh!b!t!on of th# "mylo!d form"t!on. Insul!n !s " 51 "m!no "c!d r#s!du#, wh!ch c"n r#gul"t#
th# body glucos# l#v#ls "nd !s " pot#nt !nh!b!tor of th# IAPP f!b#r form"t!on. Pr#v!ous stud!#s
!nd!c"t# th"t sto!ch!om#tr!c qu"nt!t!#s of !nsul!n c"n !nh!b!t th# form"t!on of th# IAPP f!b#rs.
Insulin may bind to a recognition site on hIAPP, interfering with its ability to self-interact to
form fibers.21

1.15. R#s#!rch Go!ls !nd Obj#ct"v#s
Typ# 2 D!"b#t#s M#ll!tus "ff#cts 150 m!ll!on p#opl# worldw!d# "nd h"s b#com# " l#"d!ng
glob"l h#"lth r!sk !n th# 21st c#ntury. D!"b#t#s !s "t #p!d#m!c proport!ons "nd cont!nu#s to
"ugm#nt glob"lly. It n##ds urg#nt "tt#nt!on to suppr#ss !ts dom!n"nc# throughout th# world. Th#
p"thology of Typ# 2 D!"b#t#s M#ll!tus !s th# d#pos!t!on of th# "mylo!d d#pos!ts !n th# beta c#lls
of th# p"ncr#"s. Th#s# d#pos!ts "r# found !n th# beta c#lls of 90% of Typ# 2 D!"b#t!c p"t!#nts
"ft#r th#!r d#"th. Furth#rmor#, !t h"s b##n "ssum#d th"t th#r# !s " r#l"t!onsh!p b#tw##n th#
hIAPP f!br!l form"t!on "nd d#v#lopm#nt of th# Typ# 2 d!"b#t#s. Th# link between hIAPP f!br!l
form"t!on "nd b#t" c#ll d#"th h"v# l#d to !ncr#"s#d !nt#r#st !n th# "ggr#g"t!on of th# "myl!n "nd
!n th# m#ch"n!sm of f!br!l form"t!on. Insul!n !s co-synth#s!z#d "nd co-s#cr#t#d "long w!th hIAPP
!n th# b#t" c#lls of th# p"ncr#"s, but !t "nt"gon!z#s th# prop#rty of f!br!l form"t!on !n th# b#t"
c#lls of th# h#"lthy !nd!v!du"l. In fact, its presence probably helps suppress fibril formation
within the secretory vesicles. Insul!n h"s two ch"!ns, th# A ch"!n "nd th# B ch"!n, wh!ch "tt"ch to
#"ch oth#r by d!sulf!d# bonds "t th# cyst#!n# r#s!du#s loc"t#d "t 2nd "nd 7th pos!t!ons. 20 Th# B
ch"!n of th# !nsul!n "cts "s a pot#nt !nh!b!tor of hIAPP ol!gom#r!z"t!on "nd f!br!l form"t!on.
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Accord!ng to G!l"#d "t #l., a d"c#p"pt!d" within !nsul!n, HLVEALYLV, !s cons!d"r"d to b" th"
cor" r"g!on of !nsul!n wh!ch c#n m#k" cont#ct w!th th" 10-19 r"g!on of hIAPP #nd pr"v"nt f!br!l
form#t!on.21
In th!s r"s"#rch, the recognition region of the natural inhibitor insulin was used to design
smaller analogs in an attempt to slow the fiber formation and membrane damage. W"
synth"s!z"d both !nsul!n #n#logs, HLVEALYLV #nd the truncated LVEALYLV, !n th"
l#bor#tory us!ng an #utom#t"d PS3 p"pt!d" synth"s!z"r. Th"s" p"pt!d"s were cl"#v"d from th"
sol!d support r"s!n and pur!f!"d, #nd th" p"pt!d" m#ss"s were confirmed by us!ng m#ss
sp"ctroscopy. Shorter sequences are economically and synthetically advantageous and may
serve as a starting point for the design of small molecules that inhibit hIAPP toxicity.
Th" !nh!b!tory stud!"s of th" insulin-based p"pt!d"s on hIAPP analogs in l!p!d m"mbr#n"
mod"ls w"r" th"n d"t"rm!n"d by us!ng a dy" l"#k#g" ass#y m"thod. Th" !nt"ns!ty of th"
d!srupt!on c#us"d by th" #ct!v" hIAPP p"pt!d"s on th" m"mbr#n" model !s d!r"ctly proport!on#l
to th" measured fluorescence !nt"ns!ty of th" dye r"l"#s"d from preformed liposomes.
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2. Exp!r"m!nt#l M!thods
Th! "nsul"n #n#logs, HLVEALYLV #nd LVEALYLV, w!r! pr!p#r!d us"ng sol"d ph#s!
p!pt"d! synth!s"s by #n #utom#t!d p!pt"d! PS3 synth!s"z!r. Th! s"ngl! coupl"ng m!thod was
us!d for th! form#t"on of th! p!pt"d! bonds of th! d!s"r!d #m"no #c"d s!qu!nc!. All of th!
solv!nts us!d for th! synth!s"s of th! p!pt"d!s w!r! ACS gr#d!, #nd Fmoc prot!ct!d #m"no #c"ds
w!r! purch#s!d from M"dw!st B"ot!ch, Inc., #nd Prot!"n T!chnolog"!s, Inc. Th! N, Nd"m!thylform#m"d! (DMF) #nd 20% p"p!rid"n! solut"on (v/v) "n DMF, O- (B!nzo-tr"#zol-1-yl)1, 1, 3, 3-t!tr#m!thyluron"um h!x#fluorophosph#t! (HBTU) #nd N, N-d""sopropyl!thyl#m"n! "n
DMF w!r! purch#s!d from F"sch!r Sc"!nt"f"c. Th! target p!pt"d!s w!r! pur"f"!d from br#nch!d
p!pt"d!s #nd oth!r "mpur"t"!s us"ng r!v!rs! ph#s! h"gh p!rform#nc! l"qu"d chrom#togr#phy (RPHPLC). Th! pur"ty of th! p!pt"d!s was conf"rm!d by us"ng an#lyt"c#l HPLC, #nd molecular
weights by !l!ctrospr#y m#ss sp!ctrometry. Th! p!rform#nc! of th! p!pt"d!s on th! s"ngl!
l#y!r!d v!s"cl!s w#s t!st!d us"ng # dy!-l!#k#g! #ss#y m!thod w"th th! h!lp of # FLx 800
Fluorescence Microplate Reader with KC4 software.

2.1.

Sol"d Ph#s! P!pt"d! Synth!s"s

Sol"d Ph#s! P!pt"d! Synth!s"s (SPPS) w#s d!v!lop!d by R. B. M!rr"f"!ld for th! synth!s"s of
p!pt"d!s #nd sm#ll prot!"ns us"ng ch!m"c#ls "n th! l#bor#tory. 22 Two m#jor forms of p!pt"d!
synth!s"s use SPPS. Th! Fmoc (fluorenylmethyloxycarbonyl) method ut"l"z!s a b#s! l"#bl! alph##m"no prot!ct"ng group, #nd the t-Boc (t-butyloxycarbonyl) method us!s an #c"d l"#bl! prot!ct"ng
group.22 Of th!s! two m!thods, th! Fmoc m!thod h#s # h"gh!r y"!ld #nd produces pur!r p!pt"d!s.
Th! g!n!r#l pr"nc"pl! "nvolv!d "n sol"d ph#s! p!pt"d! synth!s"s "s th#t on! !nd of th! p!pt"d! "s
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!tt!ch"d to th" sol#d support r"s#n, !nd th" d"s#r"d s"qu"nc" of N- $ !m#no !c#ds is built
backward from the C-terminus. Aft"r th" synth"s#s of th" p"pt#d" s"qu"nc", th" sol#d r"s#n
support c!n b" d"t!ch"d from th" p"pt#d" us#ng th" cl"!v!g" proc"dur". An outline of the
procedure can be seen in Figure 4.
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Figure 4: Sol!d Ph"s# p#pt!d# synth#s!s sch#m#. Th!s f!gur# !s "d"pt#d from r#f#r#nc# [23].

Th! g!n!r"l pr#nc#pl! #nvolv!d #n SPPS #s r!p!"t!d coupl#ng "nd d!prot!ct#on of th!
"m#no "c#ds. Th! fr!! N-t!rm#n"l "m#n! of th! sol#d ph"s! p!pt#d! growing chain #s coupl!d to
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th! s"ngl! incoming N-prot!ct!d #m"no #c"d to form an amide bond. A basic reagent (piperidine)
then c#us!s "t to b! d!prot!ct!d #g#"n so it is ready for the next coupling. A 20% p"p!r"d"n!
solut"on (v/v) "n DMF w#s us!d for d!prot!ct"on. O-(B!nzotr"#zol-1-yl)-1, 1, 3, 3t!tr#m!thyluron"um h!x#fluorophosph#t! (HBTU) w#s us!d #s # coupl"ng #g!nt, #ct"v#t!d by 0.4
M N, N–d""sopropyl!thyl#m"n! "n DMF.6 DMF is used to wash the peptide-resin between
coupling and deprotection steps. A diagram of the peptide synthesizer is shown in Figure 5.

Figure 5: D!"gr"m of th# Autom"t#d Sol!d Ph"s# P#pt!d# Synth#s!z#r.
Th!s f!gur# !s "d"pt#d from r#f#r#nc# [24].
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2.2.

Synth!s"s of Insul"n An#logs (HLVEALYLV and LVEALYLV)
Th! "m#no "c#ds in the sequence (0.4 mmoles each) w!r! "ccur"t!ly w!#gh!d "nd

tr"nsf!rr!d to th! r!sp!ct#v! v#"ls. Th!n HBTU 0.152g (0.4mmoles) w"s "dd!d to !"ch v#"l. Th!
r!sp!ct#v! v#"ls w!r! pl"c!d #n th! c"rous!l b!g#nn#ng w#th th! C- t!rm#n"l end "m#no "c#d,
proc!!ding to th! N- t!rm#n"l pos#t#on. Th!n 0.16g (0.1mmole) of MBHA (m!thyl b!nzhydryl
"m#n!) r!s#n w"s w!#gh!d "nd tr"nsf!rr!d to th! r!"ct#on v!ss!l. The PS3 was programmed to
complete the sequence, and synth!s#s of th! p!pt#d! w"s cont#nu!d to produc! th! d!s#r!d p!pt#d!
s!qu!nc! #n th! r!"ct#on v!ss!l. Onc! th! synth!s#s w"s compl!t!d, the p!pt#d! resin w"s t"k!n
out of th! r!"ct#on v!ss!l "nd subj!ct!d to cl!"v"g!.

2.3.

P!pt"d! Cl!#v#g!
Th! p!pt#d!-r!s#n w"s w"sh!d off us#ng DMF "nd m!thyl!n! chlor#d!, "nd dr#!d und!r

th! v"cuum l#n! for "pprox#m"t!ly on! hour. Th! cl!"v"g! cockt"#l w"s pr!p"r!d #n " 50 ml
b!"k!r #n "n #c! b"th by "dd#ng 0.5 ml of w"t!r, 0.5 ml of "n#sol!, " sm"ll "mount of ph!nol
cryst"ls, "nd 10 ml of tr#fluoro"c!t#c "c#d. Th! r!s#n-p!pt#d! w"s tr"nsf!rr!d to th! cockt"#l
cont"#n!d #n th! b!"k!r, "nd #t w"s subj!ct!d to st#rr#ng for "pprox#m"t!ly 2 hours "t room
t!mp!r"tur!. Th! cl!"v"g! m#xtur! w"s tr"nsf!rr!d to a co"rs! fr#tt!d gl"ss funn!l, removing the
now uncharged resin, "nd th! p!pt#d! solut#on w"s coll!ct!d #n a s#d!-"rm!d fl"sk. Th! coll!ct!d
p!pt#d! solut#on w"s m#x!d w#th 50 ml cold d#!thyl !th!r, c"us#ng th! p!pt#d! to pr!c#p#t"t! from
th! solut#on. Th! pr!c#p#t"t!d p!pt#d! solut#on w"s slowly f#lt!r!d through th! f#n! fr#tt!d gl"ss
funn!l us#ng th! v"cuum l#n!. Th! f#lt!r!d p!pt#d! w"s dr#!d for " few minutes "nd w"s !"s#ly
scr"p!d out from th! funn!l using a spatula. Th! coll!ct!d p!pt#d! w"s th!n tr"nsf!rr!d to a
lyoph#l#z"t#on fl"sk cont"#n#ng a 70% "c!tonitr#l! "nd 30% w"t!r m#xtur! and dissolved. N!xt an
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!qu"l volume of d#st#ll!d w"t!r was added to dilute the solution. Th!n th! fl"sk w"s froz!n by
b!#ng k!pt #n th! -80o C fr!!z!r for "pprox#m"t!ly "n hour "nd th!n subj!ct!d to lyoph#l#z"t#on
ov!rn#ght.

2.4.

P!pt"d! Pur"f"c#t"on #nd An#lys"s
For th! pur#f#c"t#on of th! p!pt#d!, r!v!rs!d ph"s! HPLC w"s us!d. R!v!rs!d ph"s!

HPLC works b"s!d on th! hydrophob#c n"tur! of th! p!pt#d!s. Th! solv!nts us!d w!r! 0.1%
TFA-w"t!r "nd 0.1% TFA-"c!tonitr#l!. Th! solut#ons w!r! m#x!d "nd !lut!d #n a l#n!"r gr"d#!nt
through " C18 column. The crude peptides were purified by preparative reversed-phase high
performance liquid chromatography (RP-HPLC) on a Waters (Milford, MA) instrument. A
Ph!nom!n!x Jup#t!r column (C18, 10µm, 250 x 21.20 mm, 300$) w"s us!d to obt"#n pur#f#!d
p!pt#d! from th! #mpur#t#!s. Th! mob#l! ph"s! solv!nts w!r! m"d! to run w#th " l#n!"r gr"d#!nt
of 10-50% organic component over two hours, h"v#ng " 10ml/m#n flow r"t!. Th! crude p!pt#d!
w"s w!#gh!d to ch!ck th! m"ss "nd th!n dissolved in tr#fluoro"c!t#c "c#d. Th!n th! p!pt#d! w"s
#nj!ct!d #nto th! HPLC. Th! pur! p!pt#d! w"s coll!ct!d #n t!st tub!s b"s!d on th! d!t!ct#on of th!
"bsorb"nc! "t 254nm, "nd tubes containing pure peptide (as monitored by UV absorbance) were
combined, frozen, and lyophilized.

2.5.

An#lyt"c#l HPLC
Th! pur#ty of th! p!pt#d!s w"s d!t!rm#n!d us#ng "n"lyt#c"l RP-HPLC w#th " mob#l!

ph"s! m"d! up of 0.1% TFA-w"t!r "nd 0.1% TFA-"c!ton#tr#l! solut#ons on " Phenomenex
Jupiter column (C18, 5µm, 250 x 4.6 mm) w#th a flow r"t! of 1ml/m#n. Th! pur#ty w"s m!"sur!d
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for both p!pt"d!s, HLVEALYLV and LVEALYLV, and found to be # 95% by peak integration.
Th! mol!cul$r w!"ght of th! p!pt"d!s w$s found us"ng !l!ctrospr$y m$ss sp!ctrometry. This
confirmed correct molecular weights for HLVEALYLV and LVEALYLV as 1055.3Da and
918.1 Da, respectively.

2.6.

Preparation of Lipid Unilamellar Vesicles and Dye Leakage Assay
The m$t!r"$ls us!d w!r! c$rboxyfluor!sc!"n dy! (purch$s!d from S"gm$-Aldr"ch), DOPC

(1,2-dioleoyl-sn-glycero-3-phosphocholine) and DOPS (1,2-dioleoyl-sn-glycero-3-(phospho-Lserine)). These lipids were purch$s!d from Av$nt" Pol$r L"p"ds, and structures are shown in
figures 6-7. Tr"ton-X w$s us!d $s $ d!t!rg!nt (purch$s!d from S"gm$-Aldr"ch).

Figure 6: Structure of DOPC26 (a neutral lipid)
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Figure 7: Structure of DOPS 27(a negatively charged lipid)

Th! dy!-l"p"d v!s"cl!s w!r! pr!p#r!d by !ntr#pp"ng th! c#rboxyfluor!sc!"n dy! "n th! s"ngl!
l#y!r!d l"p"d v!s"cl!s. For th"s pr!p#r#t"on, 5mg of a 7:3 mixture of DOPC: DOPS w!r! t#k!n "n
t!st tub!s #nd m"x!d w"th 2ml of chloroform. Aft!r 10 m"nut!s, th! chloroform w#s !v#por#t!d
from th! t!st tub!s us"ng n"trog!n g#s, #nd th! t!st tub!s w!r! pl#c!d "n a v#cuum d!ss"c#tor
ov!rn"ght.
Th!s! dr"!d l"p"ds could be stored "n th! fr!!z!r for long p!r"ods of t"m!. When n!!ded
for th! #ss#y, th! l"p"ds were removed from th! fr!!z!r #nd thawed #t room t!mp!r#tur! for #bout
30 m"nut!s pr"or to th! #ss#y. Th!n 5mg of th! c#rboxyfluor!sc!"n dy!, wh"ch w#s d"ssolv!d "n
500 $L of sod"um phosph#t! buff!r #t pH 7.5, w#s m"x!d w"th th! dr"!d l"p"d. Th! whol!
solut"on w#s vort!x!d for #pprox"m#t!ly on! m"nut! to m"x #ll th! compon!nts of th! solut"on.
Th!n th! solut"on w#s subj!ct!d to fr!!z! #nd th#w cycl!s for 5 t"m!s succ!ss"v!ly using dry
ice/acetone. Th! th#w!d solut"on w#s !xtrud!d 21 t"m!s to cause vesicles to become a uniform
size us"ng # M"n"-!xtrud!r (Figure 8) (purch#s!d from Av#nt" Pol#r L"p"ds). Th! !xtrus"on
proc!ss w#s difficult due to the small pore size (0.1 micron) of the polyc#rbon#t! f"lt!rs. Onc!
th! !xtrus"on proc!ss w#s compl!t!d, th! solut"on w#s tr#nsf!rr!d "nto # S!ph#d!x G50 g!l
!xclus"on column.9 G!l f"ltr#t"on chrom#togr#phy s!p#r#t!s th! l"p"d v!s"cl!s in solution b#s!d on
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s!z" !n ord"r for th" dy"-cont#!ning l!p!d v"s!cl"s to s"p#r#t" #nd "lut" from th" r"m#!n!ng free
dye. Th" first sm#ll b#nd of yellow color was coll"ct"d !n # s"p#r#t" cont#!n"r and saved for th"
dy" l"#k#g" #ss#y.

Figure 8: M!n! "xtrud"r us"d for th" size uniformity of th" v"s!cl"s.

Th" !nsul!n #n#logs (HLVEALYLV or LVEALYLV) were w"!gh"d to 1.4 mg #nd
d!ssolv"d !n 350 $L of d!m"thyl sulfox!d" (DMSO) solv"nt, then son!c#t"d for #pprox!m#t"ly
on" m!nut". In th" s#m" w#y, th" hIAPP p"pt!d" #n#log (1mg) w#s w"!gh"d #nd d!ssolv"d !n 350
$L of d!m"thyl sulfox!d" (DMSO) solv"nt to make a stock solution. Th" oth"r solut!ons us"d for
th" #ss#y w"r" pH 7.5 sod!um phosph#t" buff"r, #nd Tr!ton X-100, # d"t"rg"nt solut!on, wh!ch
w#s us"d #s th" pos!t!v" control to obt#!n 100% dy" l"#k#g" from th" l!p!d v"s!cl"s.
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To study the effect of hIAPP itself, the sample test tubes concentrations are shown in
Table 1.
Table 1: Volume of Components in Sample Tubes of hIAPP Alone

Trial

Sodium phosphate
buffer (!L)

hIAPP
(!L)

1

1441

1

20

0.5

2

1464

2.5

20

1.2

3

1489

5

20

2.4

4

1465

10

20

4.8

5

1449

12.5

20

6

6

1451.5

25

20

12

7

1479

37.5

20

18

8

1483.5

50

20

24

21

Lipid vesicles Concentration of
(!L)
hIAPP (!M)

To study the effects of variable amounts of insulin/analog with constant hIAPP, concentrations
are shown in Table 2.
Table 2: Insulin/Analog Combined Activity Assay; Amylin conc. 10 !M.

Trial

Buffer
(!L)

hIAPP
(!L)

Insulin/
Analog
(!L)

Lipid
vesicles
(!L)

Conc.
Insulin
(!M)

Ratio of
Insulin:
hIAPP

0

1475

5

0

20

0

N/A

1

1474

5

1

20

0.5

1:5

2

1472.5

5

2.5

20

1.2

1:2

3

1470

5

5

20

2.4

1:1

4

1465

5

10

20

4.8

2:1

5

1462.5

5

12.5

20

6

2.5:1

6

1450

5

25

20

12

5:1

7

1437.5

5

37.5

20

18

7.5:1

8

1425

5

50

20

24

10:1
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The volume of components in detergent and control tubes are shown in Table 3.
Table 3: Control and Detergent Tube Composition
Trial

hIAPP

Insulin

Vesicles

Buffer

DMSO

Detergent

Detergent

0

0

20

1390

50

40

Control

0 (!L)

0(!L)

20(!L)

1430
(!L)

50(!L)

0 (!L)

2.7.

Fluorescent Dy" L"#k#g" Ass#y
Th! g!n!r"l pr#nc#pl! #nvolv!d #n th! dy! l!"k"g! "ss"y w"s th"t m!mbr"n! "ct#v!

p!pt#d!s c"n c"us! th! d#srupt#on of th! v!s#cl!s, r!sulting #n th! l!"k"g! of th! fluorescent dy!
from th! v!s#cl!s. In turn, this #ncr!"s!s th! monitored fluor!sc!nc! over time. A FLx 800
fluorescence micro-plate reader (BioTek Instruments) w"s us!d to "n"lyz! th! stud#!s of th!
l!"k"g! c"us!d by th! p!pt#d!s #n th! l#p#d v!s#cl!s "t "n !xc#t"t#on of 485 nm "nd "n !m#ss#on of
528 nm over a period of 3 hours. The 7: 3 mixture of DOPC: DOPS lipid mimics the actual beta
cell membrane composition and can be used as a model for pancreatic beta cells. The
composition of assay tubes is listed in Tables 1-3. Samples were transferred to a 96-well plate for
reading. Dye leakage is calculated by the equation:
Percent Fraction Leaked = [(Value-Control)/ (Detergent-Control)]*100
The percent fraction leaked (% fluorescence) was plotted against time for each concentration
of each peptide to determine the percent membrane disruption. The hIAPP was held constant
while the concentration of synthesized inhibitor was varied, with ratios of inhibitor to hIAPP
ranging from 0.2:1 to 10:1.
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3. R!sults and Discussion
The inhibitory ability of the insulin analogs was studied on the hIAPP-induced leakage
on single layered vesicles. The 7:3 DOPC/DOPS lipid vesicles were used for the inhibitory
studies. These vesicles imitate the somatic body cells and are commonly used in liposome
models of membrane systems. DOPC is zwitterionic, while DOPS is negatively charged. The
7:3 mixture of DOPC: DOPS is considered a good model for pancreatic beta cell studies, with
30% negatively charged lipids.
The data in Figure 9 were gathered through a dye leakage assay showing the interaction
between the !-cell mimics and twelve concentrations of hIAPP. Fluorescence values were taken
every minute for three hours, and the graph was produced by using the previously described
formula for percent leakage, plotted versus time for each concentration. It should be noted that
membrane leakage increased over the time period observed, indicating the possibility of
aggregate formation. It is clear that significant damage to the vesicles is caused by high
concentrations of hIAPP as the percent leakage approaches 100% at 50 mM. Figure 10 was then
produced by averaging the percent membrane disruption at each time point and plotting these
values against concentration. This figure shows concentration dependent damage to the !-cell
membrane mimics by hIAPP. A logarithmic regression is shown with a correlation coefficient of
0.87.
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Percent Membrane Disruption Varying [1-37 hIAPP]
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Figure 9: Dye leakage from 7:3 DOPC/DOPS vesicles by varying concentrations of hIAPP
over time.
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Figure 10: Average percent of dye leakage in model membranes caused by hIAPP.

The data displayed in Figure 11 and Figure 12 were gathered through a dye leakage assay
where twelve concentrations of insulin ranging from 0 µM to 100 µM were run against a
constant 10µM hIAPP concentration, and fluorescence readings were taken every minute for
three hours. This concentration of hIAPP was chosen since it produced intermediate damage and
was a reasonable starting point, where both increases and decreases in dye leakage could be
noted. Figure 11 shows a variable effect by insulin, with no clear concentration dependence. It
is notable that the 10 µM hIAPP itself (no insulin) showed a much greater time dependence for
damage than the samples treated with insulin; the insulin seemed to have a greater effect as time
elapsed, which could indicate its role in slowing time dependent fiber formation in the later
phases of membrane damage. The plot in Figure 12 was produced by averaging the percent
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membrane disruption over time at each insulin concentration (displayed as the ratio of the
concentration of insulin to the concentration of hIAPP). It can be observed that the trial without
any insulin produces the greatest membrane disruption. This confirms that insulin does inhibit
membrane damage in this assay. However, the relationship between membrane disruption and
the ratio of insulin to hIAPP is variable. A sharp spike can be noted at the ratio of
0.2[Insulin]:1[hIAPP]. This ratio maximizes the extent of inhibition induced by insulin. At this
ratio, insulin inhibits membrane disruption by 13%. As the insulin: hIAPP ratio is increased
beyond this point, membrane disruption quickly increases to varying degrees but never
significantly surpasses the level of damage caused by hIAPP by itself.

Percent Membrane Disruption Constant [10µM
hIAPP] against Varying Insulin
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Figure 11: Percent of dye leakage from model 7:3 DOPC/DOPS liposomes in the presence
of varying concentrations of insulin and 10 µM hIAPP over time.
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One possible explanation for this observation is that hIAPP forms a five-unit complex to
which one molecule of insulin binds. This six-unit complex is less toxic than free hIAPP,
perhaps reducing its ability to interact with the membrane in a fully aggregated form. This result
is conserved over many trials and is particularly interesting given that insulin is stored in
secretory cells as a hexamer, so the six-unit complex may have some significance. However,
even at the optimal ratio, membrane damage as measured by this assay is only reduced by ~15%.
This suggests that membrane disruption may be mediated by more than simply hIAPP
aggregation and fiber formation; perhaps it is caused by transient deformations in the acyl chain
arrangements induced by interaction of the positively charged peptide with the overall negatively
charged membrane surface.
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Figure 12: Average percent of dye leakage from model membranes in the presence of
varying ratios of insulin to hIAPP.
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10

Figure 13 shows the percent dye leakage from 7:3 DOPC/DOPS vesicles in the presence
of 10 µM hIAPP and varying concentrations of the first inhibitor, HLVEALYLV, a sequence
based on the contact area between insulin and hIAPP.
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Percent Membrane Disruption Constant [10µM hIAPP]
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Figure 13: Percent of dye leakage from model 7:3 DOPC/DOPS liposomes in the presence
of varying concentrations of HLVEALYLV and 10 µM hIAPP over time.

Concentrations of inhibitor peptide were varied from 0 to 100 µM. While general
concentration dependence is visible, it can be observed that membrane damage actually
increases, rather than decreases, in the presence of the inhibitor. The greater the concentration of
HLVEALYV, the greater the dye leakage, ranging from about 30% with hIAPP alone to over
90% with hIAPP plus 100 µM peptide inhibitor. The decreasing damage over time for the two
highest concentrations is unusual and probably due to experimental error. Overall, there is a
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significant increase in dye leakage that indicates damage being caused by the synthesized
peptide. Figure 14 shows a plot of the time-averaged dye leakage at each concentration versus
the ratio of inhibitor peptide to hIAPP. From this graph, it is also clear that only the 0.2:1 ratio is
effective in lowering membrane damage and that increasing peptide concentration actually
enhances the dye leakage.
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Figure 14: Average percent of dye leakage from model membranes in the presence of
varying ratios of HVEALYLV to hIAPP.
This result is interesting because the same ratio is observed for maximum activity of
HLVEALYV and insulin, possibly supporting the model of the six-unit complex. However, the
reduction in dye leakage is only about 5%, which may be attributable to inherent error in the
assay and fluorescence readings. In addition, the very definite increase in dye leakage associated
with this peptide was not observed in the insulin trial.
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Figure 15 shows the percent dye leakage from 7:3 DOPC/DOPS vesicles in the presence
of 10 µM hIAPP and varying concentrations of the second inhibitor, LVEALYLV, which is
truncated at the N-terminus relative to the first inhibitor.

Percent Membrane Disruption Constant [10µM
hIAPP] against Varying [LVEALYLV]
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Figure 15: Percent of dye leakage from model 7:3 DOPC/DOPS liposomes in the presence
of varying concentrations of LVEALYLV and 10 µM hIAPP over time.

This graph displays the same general trend as the longer inhibitor. As the concentration
of LVEALYV increases, the damage to the vesicles increases. Except for the lowest
concentration tested (2 µM), this peptide actually enhances the effect of hIAPP and is damaging
to the vesicles. Once again, the average dye leakage over time was calculated and plotted
against the ratio of inhibitor peptide to hIAPP, Figure 16. Again, only the 0.2:1 ratio is effective
in protecting against damage, and only minimally so. All greater ratios cause a drastic increase
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in liposome damage in a concentration dependent manner, from 35% at 0 µM LVEALYLV to
almost 90% at >50 µM LVEALYV.
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Figure 16: Average percent of dye leakage from model membranes in the presence of
varying ratios of LVEALYLV to hIAPP.
Overall, the two synthesized peptides demonstrate very similar behavior, as expected,
given their similar sequences. The smaller peptides, however, behave differently from insulin at
ratios above 0.2:1 (inhibitor:hIAPP), increasing the damage to the liposomes. It is possible that,
instead of inhibiting the aggregation of hIAPP, they actually enhance or seed the aggregation. In
fact, they may co-aggregate with the hIAPP, as some researchers have reported for insulin32.
The internal sequence of insulin at the binding interface (ALYLV) is very similar to that of
hIAPP (ANFLV), so the small inhibitors may be acting unexpectedly as hIAPP analogs rather
than insulin analogs.
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4. Conclusion
The peptide insulin-based inhibitors HLVEALYLV and LVEALYLV were ineffective in
stopping the membrane damage induced by hIAPP. Only the lowest concentrations tested, those
at a 0.2:1 ratio of peptide inhibitor to hIAPP, showed inhibitory activity, and this was minimal.
While insulin itself was capable of protecting the model vesicles to a small extent, the
synthesized peptides actually enhanced the damage to the vesicles, with more dye leakage
occurring at higher concentrations. Interestingly, both small analogs had optimal activity at the
same ratio of inhibitor to hIAPP (0.2:1) as insulin, lending some support to a model of a hexamer
between five units of hIAPP and one of insulin. However, it is likely that the synthesized
peptides, which share some sequence homology with hIAPP at the binding interface, act more as
analogs of hIAPP than of insulin, promoting hIAPP’s aggregation rather than inhibiting it.

5. Future Studies
The next phase of this work will include a different assay that measures extent of
aggregation rather than liposome damage to see whether they are correlated. Thioflavin T, a dye
that fluoreses in the presence of aggregated peptides and fibers, can be used to study whether
these synthesized peptides promote, inhibit, or have no effect on the fibrilization of hIAPP. This
will shed more light on the mechanism behind the results obtained here. If aggregation is faster
in the presence of synthesized peptide, that would indicate co-aggreagtion. If aggregation is
actually slowed despite the increase in membrane damage, that would suggest that something
more than just aggregation is occurring as the mechanism of membrane damage, possibly the
formation of pores, disordering or puncturing of the membrane, or induction of curvature.
Slowing hIAPP aggregation actually may prolong the presence of a cytotoxic species.
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